Form 4: Skye Bioscience Director, Karen L. Smith, Granted Stock Options

Karen L. Smith, a director of Skye Bioscience, Inc., was granted stock options to purchase 40,000 shares of common stock on July 2, 2024.

Summary

• On July 2, 2024, Karen L. Smith, a director of Skye Bioscience, Inc., was granted stock options.
• The options allow her to purchase 40,000 shares of the company's common stock at an exercise price of $7.56 per share.
• The options vest in equal monthly installments over one year from the grant date and expire on July 1, 2034.
• Following the transaction, Ms. Smith directly owns 40,000 derivative securities.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of aligning director interests with shareholders, but it's a routine event.

Positives

• The granting of stock options to a director aligns her interests with those of the shareholders, incentivizing her to work towards increasing the company's value.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation packages.
• The vesting schedule of one year is fairly typical, although some companies may use different vesting periods.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's long-term success.

Key Dates